ARCUTIS BIOTHERAPEUTICS, INC.

ARQT

CIK 0001787306 ยท Quarterly mode ยท latest period FY2025 (Q4) (ending 2025-12-31) ยท sourced from SEC EDGAR

At a glance ยท FY2025 (Q4)

Revenue
$130M
โ†‘+81.5% +$58Mvs FY2024 (Q4)
Operating Income
$18M
Net Income
$15M
Gross Profit
$118M
โ†‘+82.8% +$53Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot ยท latest annual filed values ยท S&P 500 calibration

Strong
71/100
  • Profitability
    0ROIC -3.4% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.17 (above 1.5 = solid)
  • Leverage
    71D/E 0.58 (under 0.5 = conservative)
  • Efficiency
    57Asset Turnover 0.94x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +81.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 8.6% ยท trend +88.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation ยท trailing 4 quarters

how the company spent its cash
Capex (TTM)
$686K
investment in PP&E
Stock-based comp (TTM)
$40M
non-cash dilution

Balance sheet ยท 2025-12-31

latest filed snapshot
Total assets
$433M
everything owned
Total liabilities
$243M
everything owed
Stockholders' equity
$189M
shareholder claim
Net debt
$66M
LT debt minus cash

Recent performance ยท 28 quarters

Revenueโ†‘+81.5% +$58M
$130M
Net Incomeโ†‘+117.8% +$49M
$7M
Free Cash Flow
$26M
Operating Marginโ†‘+95.9pts
8.6%

Drill down